Overview

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Nivolumab